While the AstraZeneca/University of Oxford COVID-19 vaccine is at the center of a row about whether or not the company has broken a promise on supplies to the European Union, the all-important decision on its approval in the bloc is just days away. (Also see "Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning" - Scrip, 26 January, 2021.)
AstraZeneca Vaccine May Only Gain EU Approval In Under 70s
Limited Data Creates Conundrum For Regulator
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
More from Europe
• By
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
• By
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
• By
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry
• By
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.